WO2011015918A3 - Vectors and compounds for expression of recombinant cetuximab - Google Patents

Vectors and compounds for expression of recombinant cetuximab Download PDF

Info

Publication number
WO2011015918A3
WO2011015918A3 PCT/IB2010/001895 IB2010001895W WO2011015918A3 WO 2011015918 A3 WO2011015918 A3 WO 2011015918A3 IB 2010001895 W IB2010001895 W IB 2010001895W WO 2011015918 A3 WO2011015918 A3 WO 2011015918A3
Authority
WO
WIPO (PCT)
Prior art keywords
cetuximab
compounds
expression
vectors
recombinant
Prior art date
Application number
PCT/IB2010/001895
Other languages
French (fr)
Other versions
WO2011015918A2 (en
Inventor
Villoo Morawala Patell
Sami N. Guzder
Sunit Maity
Sunil Shekar
Original Assignee
Avesthagen Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avesthagen Limited filed Critical Avesthagen Limited
Publication of WO2011015918A2 publication Critical patent/WO2011015918A2/en
Publication of WO2011015918A3 publication Critical patent/WO2011015918A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element

Abstract

The present invention relates to obtain a novel expression vectors and compounds of expression of recombinant anti-human epidermal growth factor receptor monoclonal antibody protein. The present invention further relates to use of novel expression vector carrying Scaffold/Matrix Attachment Region (S/MAR) to produce Cetuximab in larger quantity, which can be useful for biotechnology and pharmaceutical industries.
PCT/IB2010/001895 2009-08-03 2010-08-02 Vectors and compounds for expression of recombinant cetuximab WO2011015918A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1842CH2009 2009-08-03
IN1842/CHE/2009 2009-08-03

Publications (2)

Publication Number Publication Date
WO2011015918A2 WO2011015918A2 (en) 2011-02-10
WO2011015918A3 true WO2011015918A3 (en) 2011-04-21

Family

ID=43544726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/001895 WO2011015918A2 (en) 2009-08-03 2010-08-02 Vectors and compounds for expression of recombinant cetuximab

Country Status (1)

Country Link
WO (1) WO2011015918A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1006141B8 (en) 2009-01-12 2021-05-25 Cytomx Therapeutics Llc modified antibody compositions, methods of making and using the same
CA2895316C (en) * 2012-12-20 2019-12-03 Archer-Daniels-Midland Company Biofuels production from bio-derived carboxylic-acid esters

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074969A2 (en) * 2001-01-26 2002-09-26 University Of Lausanne Matrix attachment regions and methods for use thereof
WO2003024199A2 (en) * 2001-09-21 2003-03-27 Avigenics, Inc. Production of transgenic avians using sperm-mediated transfection
EP1362868A2 (en) * 1991-03-06 2003-11-19 MERCK PATENT GmbH Humanized and chimeric monoclonal antibodies that bind epidermal growth factor receptor (EGF-R)
WO2005047512A2 (en) * 2003-11-12 2005-05-26 Shering Corporation Plasmid system for multigene expression
WO2008142124A1 (en) * 2007-05-21 2008-11-27 Vivalis Recombinant protein production in avian ebx® cells
WO2010018444A2 (en) * 2008-08-12 2010-02-18 Avesthagen Limited An expression vector and a method thereof
WO2010049777A1 (en) * 2008-10-28 2010-05-06 Avesthagen Limited An expression vector and processes thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1362868A2 (en) * 1991-03-06 2003-11-19 MERCK PATENT GmbH Humanized and chimeric monoclonal antibodies that bind epidermal growth factor receptor (EGF-R)
WO2002074969A2 (en) * 2001-01-26 2002-09-26 University Of Lausanne Matrix attachment regions and methods for use thereof
WO2003024199A2 (en) * 2001-09-21 2003-03-27 Avigenics, Inc. Production of transgenic avians using sperm-mediated transfection
WO2005047512A2 (en) * 2003-11-12 2005-05-26 Shering Corporation Plasmid system for multigene expression
WO2008142124A1 (en) * 2007-05-21 2008-11-27 Vivalis Recombinant protein production in avian ebx® cells
WO2010018444A2 (en) * 2008-08-12 2010-02-18 Avesthagen Limited An expression vector and a method thereof
WO2010049777A1 (en) * 2008-10-28 2010-05-06 Avesthagen Limited An expression vector and processes thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GIROD, P-A. ET AL.: "Use of the chicken lysozyme 5' matrix attachment region to generate high producer CHO cell lines", BIOTECHNOLOGY AND BIOENGINEERING, vol. 91, no. 1, 2005, pages 1 - 11, XP002465966, DOI: doi:10.1002/bit.20563 *
ZAHN-ZABAL, M. ET AL.: "Development of stable cell lines for production or regulated expression using matrix attachment regions", JOURNAL OF BIOTECHNOLOGY, vol. 87, 2001, pages 29 - 42, XP004231294, DOI: doi:10.1016/S0168-1656(00)00423-5 *

Also Published As

Publication number Publication date
WO2011015918A2 (en) 2011-02-10

Similar Documents

Publication Publication Date Title
BR112012004221A2 (en) "antibodies, pharmaceutical composition, antibody use, nucleic acid, expression vectors, prokaryotic host cell, and method for producing a recombinant humanized antibody"
MX2018013738A (en) Antibodies comprising chimeric constant domains.
TN2013000076A1 (en) Anti-ox40 antibodies and methods of using the same
WO2013059885A3 (en) Polypeptide constructs and uses thereof
WO2010120514A3 (en) Antigen-binding proteins comprising recombinant protein scaffolds
WO2012027328A3 (en) Anti-ox40 antibodies and methods of using the same
WO2013040142A3 (en) Bioinformatic processes for determination of peptide binding
NZ701825A (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
MX2009013558A (en) Lyophilized immunoglobulin formulations and methods of preparation.
EP2304440A4 (en) Novel monoclonal antibodies against hpv proteins
WO2009036209A3 (en) Homogeneous antibody populations
WO2009114702A3 (en) Recombinant production of authentic human proteins using human cell expression systems
WO2014080401A3 (en) Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
UA97516C2 (en) Fully human anti-vap-1 monoclonal antibody
MX354243B (en) Antibody polypeptides that antagonize cd40.
MX357944B (en) Antibody variants and uses thereof.
SG10201407935YA (en) Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)
WO2012054929A3 (en) Use of human serum albumin to decrease antigenicity of therapeutic proteins
MY166152A (en) Anti-human xcr1 antibodies
WO2011050985A8 (en) Clonal expansion of b cells
EP2281003A4 (en) Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
BRPI0921261A2 (en) antibodies that immunospecifically bind to modified human igf-1 peptides, hybridoma, isolated polypeptide, nucleic acid encoding an antibody, vector comprising a nucleic acid, host cell comprising a vector, improved enzyme linked immunosorbent assay (elisa), method of maintaining optimal dose of modified igf-1 / e, improved affinity chromatographic method and use of modified igf-1 / e.
WO2011015918A3 (en) Vectors and compounds for expression of recombinant cetuximab
WO2011055897A3 (en) Fusion protein binding specifically to constant region of antibody, preparation thereof and method for isolating antibody using the same
MY166974A (en) Anti-human epo receptor antibodies and method of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10806104

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10806104

Country of ref document: EP

Kind code of ref document: A2